Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
139 hedge funds and large institutions have $712M invested in Taro Pharmaceutical Industries Ltd. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 20 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $731M → $712M (-$19M)
8% less funds holding
Funds holding: 151 → 139 (-12)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$53.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.3M |
| 3 |
FCH
Freestone Capital Holdings
Seattle,
Washington
|
+$6.35M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$5.92M |
| 5 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$26.7M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$24M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.9M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
-$10.8M |
TARO Hedge Fund Activity: Q1 2017 in Review
139 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2017, worth a combined $712M — down 2.6% from $731M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TARO and 15 opened new positions — a net loss of 5 holders — while 45 trimmed existing stakes and 55 added.
The largest buyer was BlackRock, adding an estimated $53.9M. The largest seller was Renaissance Technologies, cutting an estimated $26.7M.
- 139 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2017, down from 151 in Q4 2016.
- Funds reported $712M of Taro Pharmaceutical Industries Ltd. stock for Q1 2017, down 2.6% quarter-over-quarter.
- 15 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2017 and 20 closed out, a net change of -5 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2017 was BlackRock, an estimated $53.9M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2017 was Renaissance Technologies, an estimated $26.7M sold.
Based on aggregated 13F filings for Q1 2017.